Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386280309> ?p ?o ?g. }
- W4386280309 abstract "Objective The role of thrombin in vascular pathology is a focus of investigation. The incorporation of direct Factor-Xa inhibition into practice patterns is based on its theoretical dual-pathway attenuation of both thrombin generation and platelet aggregation. However, quantification of the effect of direct anti-Xa medications on platelet function is not established. Thromboelastography with Platelet Mapping (TEG-PM) leverages dual-pathway metrics to provide comprehensive coagulation profiles. We evaluated the effects of direct oral anticoagulants (DOACs) on coagulation and platelet function profiles and correlate these data with post-operative Major Adverse Limb Events (MALE) in patients with PAD. Methods We conducted a prospective study of patients undergoing lower extremity revascularization with serial perioperative TEG-PM analysis. Patients on DOACs were compared to those not on DOACs, and stratified by concurrent mono- or dual-antiplatelet regimens (MAPT/DAPT). Post-operative MALE was recorded and difference in antithrombotic regimens and TEG-PM analysis compared between groups. Results 471 samples from 141 patients were analyzed. 29.5% were reflective of circulating DOAC therapy. Compared to MAPT alone, patients on DOAC+MAPT exhibited longer time to clot formation (R-time) [7.4(±2.4) vs. 6.7(±2.7); p<.02], but less platelet inhibition. Patients on DAPT exhibited greater platelet inhibition compared to either group [23.7(±26.9) vs. 31.0(±28.3) vs. 42.2(±31.2); p<.01]. Patients who experienced MALE were more likely to be on DOAC therapy [43.8% vs. 22.0% p=.02]. TEG-PM analysis from patients who experienced MALE also demonstrated longer R-time [8.6(±3.9 vs. 7.3(±3.0); p=.05] and increased Maximum Clot Amplitude (MA) [66.7(±4.2) vs. 61.8(±8.2); p=0.001]. Conclusion DOAC therapy resulted in a prolonged R-time but had no impact on platelet inhibition. Patients who experienced MALE were more often on DOACs and demonstrated an increased R-time, but also showed greater platelet reactivity evident by increased MA, suggesting DOACs may not be effective at protecting against MALE. Further research comparing DOAC therapy to a dual-antiplatelet approach may add clarity to emerging multimodal antithrombotic recommendations." @default.
- W4386280309 created "2023-08-31" @default.
- W4386280309 creator A5007628817 @default.
- W4386280309 creator A5011866823 @default.
- W4386280309 creator A5015664857 @default.
- W4386280309 creator A5038842072 @default.
- W4386280309 creator A5043584390 @default.
- W4386280309 creator A5051730303 @default.
- W4386280309 creator A5060822014 @default.
- W4386280309 creator A5067561635 @default.
- W4386280309 creator A5079901205 @default.
- W4386280309 creator A5080976659 @default.
- W4386280309 date "2023-08-01" @default.
- W4386280309 modified "2023-09-29" @default.
- W4386280309 title "Impact of Factor Xa Inhibition on Coagulation, Platelet Reactivity and Thrombosis in Patients with Peripheral Artery Disease" @default.
- W4386280309 cites W1983760732 @default.
- W4386280309 cites W1985018076 @default.
- W4386280309 cites W1994717241 @default.
- W4386280309 cites W2018777979 @default.
- W4386280309 cites W2056425903 @default.
- W4386280309 cites W2127897756 @default.
- W4386280309 cites W2132793593 @default.
- W4386280309 cites W2142827468 @default.
- W4386280309 cites W2154400398 @default.
- W4386280309 cites W2156688240 @default.
- W4386280309 cites W2313923636 @default.
- W4386280309 cites W2594877709 @default.
- W4386280309 cites W2741350673 @default.
- W4386280309 cites W2749380187 @default.
- W4386280309 cites W2790180402 @default.
- W4386280309 cites W2803628047 @default.
- W4386280309 cites W2945248423 @default.
- W4386280309 cites W2990657953 @default.
- W4386280309 cites W3013428853 @default.
- W4386280309 cites W3037958843 @default.
- W4386280309 cites W3212935132 @default.
- W4386280309 cites W4224067811 @default.
- W4386280309 cites W4284882124 @default.
- W4386280309 cites W4292702794 @default.
- W4386280309 cites W4292843018 @default.
- W4386280309 cites W4311999013 @default.
- W4386280309 cites W4313523211 @default.
- W4386280309 doi "https://doi.org/10.1016/j.avsg.2023.08.004" @default.
- W4386280309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37657677" @default.
- W4386280309 hasPublicationYear "2023" @default.
- W4386280309 type Work @default.
- W4386280309 citedByCount "0" @default.
- W4386280309 crossrefType "journal-article" @default.
- W4386280309 hasAuthorship W4386280309A5007628817 @default.
- W4386280309 hasAuthorship W4386280309A5011866823 @default.
- W4386280309 hasAuthorship W4386280309A5015664857 @default.
- W4386280309 hasAuthorship W4386280309A5038842072 @default.
- W4386280309 hasAuthorship W4386280309A5043584390 @default.
- W4386280309 hasAuthorship W4386280309A5051730303 @default.
- W4386280309 hasAuthorship W4386280309A5060822014 @default.
- W4386280309 hasAuthorship W4386280309A5067561635 @default.
- W4386280309 hasAuthorship W4386280309A5079901205 @default.
- W4386280309 hasAuthorship W4386280309A5080976659 @default.
- W4386280309 hasConcept C126322002 @default.
- W4386280309 hasConcept C164705383 @default.
- W4386280309 hasConcept C188816634 @default.
- W4386280309 hasConcept C2777015399 @default.
- W4386280309 hasConcept C2777664302 @default.
- W4386280309 hasConcept C2778382381 @default.
- W4386280309 hasConcept C2780868729 @default.
- W4386280309 hasConcept C3018697912 @default.
- W4386280309 hasConcept C31174226 @default.
- W4386280309 hasConcept C42219234 @default.
- W4386280309 hasConcept C71924100 @default.
- W4386280309 hasConcept C89560881 @default.
- W4386280309 hasConcept C90924648 @default.
- W4386280309 hasConceptScore W4386280309C126322002 @default.
- W4386280309 hasConceptScore W4386280309C164705383 @default.
- W4386280309 hasConceptScore W4386280309C188816634 @default.
- W4386280309 hasConceptScore W4386280309C2777015399 @default.
- W4386280309 hasConceptScore W4386280309C2777664302 @default.
- W4386280309 hasConceptScore W4386280309C2778382381 @default.
- W4386280309 hasConceptScore W4386280309C2780868729 @default.
- W4386280309 hasConceptScore W4386280309C3018697912 @default.
- W4386280309 hasConceptScore W4386280309C31174226 @default.
- W4386280309 hasConceptScore W4386280309C42219234 @default.
- W4386280309 hasConceptScore W4386280309C71924100 @default.
- W4386280309 hasConceptScore W4386280309C89560881 @default.
- W4386280309 hasConceptScore W4386280309C90924648 @default.
- W4386280309 hasLocation W43862803091 @default.
- W4386280309 hasLocation W43862803092 @default.
- W4386280309 hasOpenAccess W4386280309 @default.
- W4386280309 hasPrimaryLocation W43862803091 @default.
- W4386280309 hasRelatedWork W1999841034 @default.
- W4386280309 hasRelatedWork W2041275165 @default.
- W4386280309 hasRelatedWork W2414874060 @default.
- W4386280309 hasRelatedWork W2492982476 @default.
- W4386280309 hasRelatedWork W2769462736 @default.
- W4386280309 hasRelatedWork W2892474566 @default.
- W4386280309 hasRelatedWork W4254662573 @default.
- W4386280309 hasRelatedWork W4376129094 @default.
- W4386280309 hasRelatedWork W52452193 @default.
- W4386280309 hasRelatedWork W96873760 @default.
- W4386280309 isParatext "false" @default.
- W4386280309 isRetracted "false" @default.